185132-66-5

Basic information

• Product Name: tert-butyl 4-([1,1'-biphenyl]-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate
• Synonyms: tert-butyl 4-([1,1'-biphenyl]-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate
• CAS NO: 185132-66-5
• Molecular Weight: 335.446
• Mol File: 185132-66-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-([1,1'-biphenyl]-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-([1,1'-biphenyl]-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate(185132-66-5)
• EPA Substance Registry System: tert-butyl 4-([1,1'-biphenyl]-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate(185132-66-5)

Safety Data

• Hazardous Substances Data: 185132-66-5(Hazardous Substances Data)

Upstream product

• 5122-95-2 3-Biphenylboronic acid 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 185132-64-3 4-biphenyl-3-yl-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester 
• 103068-18-4 [(1,1'-biphenyl)-3-yl]magnesium bromide 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 2113-57-7 3-bromobiphenyl 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 

Downstream Products

• 1580440-40-9 tert-butyl 4-([1,1'-biphenyl]-3-yl)piperidine-1-carboxylate 
• 186185-90-0 4-([1,1'-biphenyl]-3-yl)piperidine 
• 932720-77-9 4-biphenyl-3-yl-1,2,3,6-tetrahydro-pyridine hydrochloride 
• 725739-60-6 4-biphenyl-3-yl-3,6-dihydro-2H-pyridine-1-sulfonyl chloride 
• 185132-68-7 4-biphenyl-3-yl-1,2,3,6-tetrahydro-pyridine 

Relevant articles and documents

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.

4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS

Compounds of the present invention having the formula (I) exhibit inhibitory activity on the natural enzyme renin. Thus, compounds of formula (I) may be employed for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.